Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

References

• Skinner D, Keffer CS. Significance of bacteremia caused by Staphylococcus aureus: a study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Internal Med. 1941;68:851–875. doi: 10.1001/archinte.1941.00200110003001
   Google Scholar
• Hamilton F, MacGowan A. A long history of β-lactams for MRSA. Nat Microbiol. 2019 Oct;4(10):1604–1605. PMID: 31541207. doi: 10.1038/s41564-019-0561-z
   PubMed Web of Science ®Google Scholar
• Sakr A, Brégeon F, Mège JL, et al. Staphylococcus aureus nasal colonization: an update on mechanisms, epidemiology, risk factors, and subsequent infections. Front Microbiol. 2018 Oct 8;9:2419. PMID: 30349525; PMCID: PMC6186810. 10.3389/fmicb.2018.02419.
   PubMed Web of Science ®Google Scholar
• Perl TM, Cullen JJ, Wenzel RP, et al. Mupirocin and the risk of Staphylococcus Aureus Study Team. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002 Jun 13;346(24):1871–7. PMID: 12063371. doi: 10.1056/NEJMoa003069
   PubMed Web of Science ®Google Scholar
• Control, E. C. f. D. P. a. Healthcare-associated infections: surgical site infections. In: ECDC. Annual epidemiological report for 2018-2020. European Centre for Disease Prevention and Control; 2021.
   Google Scholar
• Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004 Aug 21-27;364(9435):703–5. PMID: 15325835. doi:10.1016/S0140-6736(04)16897-9
   PubMed Web of Science ®Google Scholar
• Katneni R, Hedayati SS. Central venous catheter-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-based management. Nat Clin Pract Nephrol. 2007 May;3(5):256–66. PMID: 17457359. doi: 10.1038/ncpneph0447
   PubMedGoogle Scholar
• Nguyen MH, Kauffman CA, Goodman RP, et al. Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann Intern Med. 1999 Feb 2;130(3):221–225. PMID: 10049200. doi: 10.7326/0003-4819-130-3-199902020-00026
   PubMed Web of Science ®Google Scholar
• Honda H, Krauss MJ, Coopersmith CM, et al. Staphylococcus aureus nasal colonization and subsequent infection in intensive care unit patients: does methicillin resistance matter? Infect Control Hosp Epidemiol. 2010 Jun;31(6):584–91. PMID: 20426656; PMCID: PMC4154586. doi: 10.1086/652530
   PubMed Web of Science ®Google Scholar
• Control ECFDP. Healthcare associated infections acquired in intensive care units. In: ECDC. Annual epidemiological report for 2018 ( a). European Centre for Disease Prevention and Control; 2020.
   Google Scholar
• von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group N Engl J Med. 2001 Jan 4;344(1):11–16. PMID: 11136954. doi:10.1056/NEJM200101043440102
   PubMed Web of Science ®Google Scholar
• VandenBergh MF, Yzerman EP, van Belkum A, et al. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol. 1999 Oct;37(10):3133–3140. PMID: 10488166; PMCID: PMC85511. doi: 10.1128/JCM.37.10.3133-3140.1999
   PubMed Web of Science ®Google Scholar
• Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997 Jul;10(3):505–20. PMID: 9227864; PMCID: PMC172932. doi: 10.1128/CMR.10.3.505
   PubMed Web of Science ®Google Scholar
• Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005 Dec;5(12):751–62. PMID: 16310147. doi: 10.1016/S1473-3099(05)70295-4
   PubMed Web of Science ®Google Scholar
• Muthukrishnan G, Lamers RP, Ellis A, et al. Longitudinal genetic analyses of Staphylococcus aureus nasal carriage dynamics in a diverse population. BMC Infect Dis. 2013 May 16;13:221. PMID: 23679038; PMCID: PMC3673815. doi: 10.1186/1471-2334-13-221
   PubMed Web of Science ®Google Scholar
• Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med. 1991 Jan 15;114(2):101–6. PMID: 1898585. doi: 10.7326/0003-4819-114-2-101
   PubMed Web of Science ®Google Scholar
• Del Rio A, Cervera C, Moreno A, et al. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2009 May 15;48 Suppl 4:S246–53. PMID: 19374580. doi: 10.1086/598187
   PubMed Web of Science ®Google Scholar
• Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008 May 1;197(9): 1226–1234. PMID: 18422434. 10.1086/533494.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629–655. Epub 2022 Jan 19. Erratum in: Lancet. 2022 Oct 1;400(10358):1102. PMID: 35065702; PMCID: PMC8841637. doi: 10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 2002 May 28;99(11):7687–92. PMID: 12032344; PMCID: PMC124322. doi:10.1073/pnas.122108599
   PubMed Web of Science ®Google Scholar
• Control, E. C. f. D. P. a. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2021. European Centre for Disease Prevention and Control; 2022.
   Google Scholar
• Talbot GH, Jezek A, Murray BE, et al. The infectious diseases Society of America’s 10 × ’20 Initiative (10 New systemic antibacterial agents US Food and Drug Administration approved by 2020): Is 20 × ’20 a possibility? Clin Infect Dis. 2019 Jun 18;69(1):1–11. PMID: 30715222. doi: 10.1093/cid/ciz089
   PubMed Web of Science ®Google Scholar
• De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020 May 13;33(3):e00181–19. PMID: 32404435; PMCID: PMC7227449. doi: 10.1128/CMR.00181-19
   PubMed Web of Science ®Google Scholar
• Kern WV, Rieg S. Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect. 2020 Feb;26(2):151–157. Epub 2019 Nov 9. PMID: 31712069. doi: 10.1016/j.cmi.2019.10.031
   PubMed Web of Science ®Google Scholar
• Laupland KB, Lyytikäinen O, Søgaard M, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect. 2013 May;19(5):465–471. Epub 2012 May 23. PMID: 22616816. doi: 10.1111/j.1469-0691.2012.03903.x
   PubMed Web of Science ®Google Scholar
• Hindy JR, Quintero-Martinez JA, Lee AT, et al. Incidence trends and epidemiology of Staphylococcus aureus bacteremia: a systematic review of population-based studies. Cureus. 2022 May 29;14(5):e25460. PMID: 35774691; PMCID: PMC9239286. doi: 10.7759/cureus.25460
   PubMed Web of Science ®Google Scholar
• Nambiar K, Seifert H, Rieg S, et al. Survival following Staphylococcus aureus bloodstream infection: A prospective multinational cohort study assessing the impact of place of care. J Infect. 2018 Dec;77(6):516–525. Epub 2018 Sep 1. PMID: 30179645. doi: 10.1016/j.jinf.2018.08.015
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Feb 17;391(10121):668–678. Epub 2017 Dec 14. PMID: 29249276; PMCID: PMC5820409. doi:10.1016/S0140-6736(17)32456-X
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Hsueh PR, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00355–19. PMID: 31010862; PMCID: PMC6591610. doi: 10.1128/AAC.00355-19
   PubMed Web of Science ®Google Scholar
• Kaasch AJ, Barlow G, Edgeworth JD, et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect. 2014 Mar;68(3):242–251. Epub 2013 Nov 16. Erratum in: J Infect. 2014 Sep;69(3):306-7. PMID: 24247070; PMCID: PMC4136490. doi: 10.1016/j.jinf.2013.10.015
   PubMed Web of Science ®Google Scholar
• Tabah A, Laupland KB. Update on Staphylococcus aureus bacteraemia. Curr Opin Crit Care. 2022 Oct 1;28(5):495–504. Epub 2022 Aug 4. PMID: 35942696. doi: 10.1097/MCC.0000000000000974
   PubMed Web of Science ®Google Scholar
• Asgeirsson H, Thalme A, Weiland O. Staphylococcus aureus bacteraemia and endocarditis - epidemiology and outcome: a review. Infect Dis. 2018 Mar;50(3):175–192. Epub 2017 Nov 6. PMID: 29105519. doi: 10.1080/23744235.2017.1392039
   PubMed Web of Science ®Google Scholar
• Braquet P, Alla F, Cornu C, et al. Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study. Clin Microbiol Infect. 2016 Nov;22(11):948.e1–948.e7. Epub 2016 Aug 8. PMID: 27515395. doi: 10.1016/j.cmi.2016.07.034
   PubMed Web of Science ®Google Scholar
• Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015 Jul;28(3):603–661. PMID: 26016486; PMCID: PMC4451395. DOI:10.1128/CMR.00134-14
   PubMed Web of Science ®Google Scholar
• Keynan Y, Rubinstein E. Staphylococcus aureus bacteremia, risk factors, complications, and management. Crit Care Clin. 2013 Jul;29(3):547–562. PMID: 23830653. doi: 10.1016/j.ccc.2013.03.008
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States. MMWR Morb Mortal Wkly Rep. 2019 Mar 8;68(9):214–219. PMID: 30845118; PMCID: PMC6421967. doi: 10.15585/mmwr.mm6809e1
   PubMed Web of Science ®Google Scholar
• Gagliotti C, Högberg LD, Billström H, et al. Staphylococcus aureus bloodstream infections: diverging trends of meticillin-resistant and meticillin-susceptible isolates, EU/EEA, 2005 to 2018. Euro Surveill. 2021 Nov;26(46):2002094. PMID: 34794536; PMCID: PMC8603406. doi: 10.2807/1560-7917.ES.2021.26.46.2002094
   PubMedGoogle Scholar
• Yu F, Chen Z, Liu C, et al. Prevalence of Staphylococcus aureus carrying Panton-Valentine leukocidin genes among isolates from hospitalised patients in China. Clin Microbiol Infect. 2008 Apr;14(4):381–384.
   PubMed Web of Science ®Google Scholar
• Yarovoy JY, Monte AA, Knepper BC, et al. Epidemiology of community-onset Staphylococcus aureus bacteremia. West J Emerg Med. 2019 May;20(3):438–442. Epub 2019 Apr 16. PMID: 31123543; PMCID: PMC6526880. doi: 10.5811/westjem.2019.2.41939
   PubMed Web of Science ®Google Scholar
• Horino T, Hori S. Metastatic infection during Staphylococcus aureus bacteremia. J Infect Chemother. 2020 Feb;26(2):162–169. Epub 2019 Oct 30. PMID: 31676266. doi: 10.1016/j.jiac.2019.10.003
   PubMed Web of Science ®Google Scholar
• Bai AD, Showler A, Burry L, et al. Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study. Clin Infect Dis. 2015 May 15;60(10):1451–61. Epub 2015 Feb 20. PMID: 25701854. doi: 10.1093/cid/civ120
   PubMed Web of Science ®Google Scholar
• Goto M, Schweizer ML, Vaughan-Sarrazin MS, et al. Association of evidence-based care processes with mortality in Staphylococcus aureus bacteremia at veterans health administration hospitals, 2003-2014. JAMA Intern Med. 2017 Oct 1;177(10):1489–1497. Erratum in: JAMA Intern Med. 2017 Oct 1;177(10):1544. PMID: 28873140; PMCID: PMC5710211. doi: 10.1001/jamainternmed.2017.3958
   PubMed Web of Science ®Google Scholar
• Paulsen J, Solligård E, Damås JK, et al. The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review. Open Forum Infect Dis. 2016 Mar 1;3(2):ofw048. PMID: 27047985; PMCID: PMC4817315. doi:10.1093/ofid/ofw048
   PubMed Web of Science ®Google Scholar
• Pérez-Rodríguez MT, Sousa A, López-Cortés LE, et al. Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality in Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2019 Apr 1;74(4):1101–1107. doi: 10.1093/jac/dky556
   PubMed Web of Science ®Google Scholar
• Moormeier DE, Bayles KW. Staphylococcus aureus biofilm: a complex developmental organism. Mol Microbiol. 2017 May;104(3):365–376. Epub 2017 Mar 8. PMID: 28142193; PMCID: PMC5397344. doi: 10.1111/mmi.13634
   PubMed Web of Science ®Google Scholar
• Tande AJ, Palraj BR, Osmon DR, et al. Clinical presentation, risk factors, and outcomes of hematogenous prosthetic joint infection in patients with Staphylococcus aureus bacteremia. Am J Med. 2016;129:221.e11–20. doi: 10.1016/j.amjmed.2015.09.006
   PubMed Web of Science ®Google Scholar
• Østergaard L, Voldstedlund M, Bruun NE, et al. Prevalence and mortality of infective endocarditis in community-acquired and healthcare-associated Staphylococcus aureus bacteremia: a Danish nationwide registry-based cohort study. Open Forum Infect Dis. 2022 Dec 16;9(12):ofac647. PMID: 36540385; PMCID: PMC9757695. doi:10.1093/ofid/ofac647
   PubMed Web of Science ®Google Scholar
• Green J, Howard J, Shankar A, et al. Assessing the impact of a ‘bundle of care’ approach to Staphylococcus aureus bacteraemia in a tertiary hospital. Infect Prev Pract. 2020 Sep 25;2(4):100096. PMID: 34368726; PMCID: PMC8336039. doi: 10.1016/j.infpip.2020.100096
   PubMedGoogle Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18–55. * Epub 2011 Jan 4. Erratum in: Clin Infect Dis. 2011 Aug 1;53(3):319. PMID: 21208910. doi: 10.1093/cid/ciq146
   PubMed Web of Science ®Google Scholar
• López-Cortés LE, Del Toro MD, Gálvez-Acebal J, et al. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis. 2013 Nov;57(9):1225–33. * Epub 2013 Aug 8. PMID: 23929889. doi: 10.1093/cid/cit499
   PubMed Web of Science ®Google Scholar
• Nagao M, Yamamoto M, Matsumura Y, et al. Complete adherence to evidence-based quality-of-care indicators for Staphylococcus aureus bacteremia resulted in better prognosis. Infection. 2017 Feb;45(1):83–91. Epub 2016 Oct 5. PMID: 27709434. doi: 10.1007/s15010-016-0946-3
   PubMed Web of Science ®Google Scholar
• Gatley EM, Boyles T, Dlamini S, et al. Adherence to a care bundle for Staphylococcus aureus bacteraemia: A retrospective cohort study. S Afr J Infect Dis. 2022 Nov 22;37(1): 445. PMID: 36483573; PMCID: PMC9724142. 10.4102/sajid.v37i1.445.
   PubMed Web of Science ®Google Scholar
• Hadano Y, Kakuma T, Matsumoto T, et al. Reduction of 30-day death rates from Staphylococcus aureus bacteremia by mandatory infectious diseases consultation: comparative study interventions with and without an infectious disease specialist. Int J Infect Dis. 2021 Feb;103:308–315. Epub 2020 Dec 2. PMID: 33278619: doi: 10.1016/j.ijid.2020.11.199
   PubMed Web of Science ®Google Scholar
• Papadimitriou-Olivgeris M, Caruana G, Senn L, et al. Predictors of mortality of Staphylococcus aureus bacteremia among patients hospitalized in a Swiss University Hospital and the role of early source control; a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2023 Mar;42(3):347–357. Epub 2023 Feb 2. PMID: 36729318; PMCID: PMC9892677. doi: 10.1007/s10096-023-04557-1
   PubMed Web of Science ®Google Scholar
• Callejo-Torre F, Eiros Bouza JM, Olaechea Astigarraga P, et al. Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission. Infez Med. 2016;24:201–209.
   PubMedGoogle Scholar
• Yeager SD, Oliver JE, Shorman MA, et al. Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections. Int J Antimicrob Agents. 2021 May;57(5):106329. doi: 10.1016/j.ijantimicag.2021.106329
   PubMed Web of Science ®Google Scholar
• Habib G, Lancellotti P, Antunes MJ, et al. ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–3128. doi: 10.1093/eurheartj/ehv319
   PubMed Web of Science ®Google Scholar
• Blomström-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace. 2020 Apr 1;22(4):515–549. PMID: 31702000; PMCID: PMC7132545. doi: 10.1093/europace/euz246
   PubMed Web of Science ®Google Scholar
• Berbari EF, Kanj SS, Kowalski TJ, et al. Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61:e26–e46. doi: 10.1093/cid/civ482
   PubMed Web of Science ®Google Scholar
• Orr HW. The treatment of acute osteomyelitis by drainage and rest. 1927. Clin Orthop Relat Res. 2006;451:4–9. doi: 10.1097/01.blo.0000238778.34939.66
   PubMedGoogle Scholar
• Bouji N, Wen S, Dietz MJ. Intravenous antibiotic duration in the treatment of prosthetic joint infection: systematic review and meta-analysis. J Bone Jt Infect. 7(5): PMID: 36267262; PMCID: PMC9562697:191–202. 2022 Sep 19. 10.5194/jbji-7-191-2022
   PubMedGoogle Scholar
• Bernard L, Arvieux C, Brunschweiler B, et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med. 2021 May 27;384(21):1991–2001. PMID: 34042388. doi: 10.1056/NEJMoa2020198
   PubMed Web of Science ®Google Scholar
• Pradier M, Nguyen S, Robineau O, et al. Suppressive antibiotic therapy with oral doxycycline for Staphylococcus aureus prosthetic joint infection: a retrospective study of 39 patients. Int J Antimicrob Agents. 2017 Sep;50(3):447–452. Epub 2017 Jun 28. PMID: 28668689. doi: 10.1016/j.ijantimicag.2017.04.019
   PubMed Web of Science ®Google Scholar
• Lam JC, Stokes W. The golden grapes of wrath - Staphylococcus aureus bacteremia: a clinical review. Am J Med. 2023 Jan;136(1):19–26. * Epub 2022 Sep 28. PMID: 36179908. doi: 10.1016/j.amjmed.2022.09.017
   PubMed Web of Science ®Google Scholar
• Chong YP, Moon SM, Bang K-M, et al. Treatment duration for uncomplicated staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother. 2013;57(3):1150–1156. doi: 10.1128/AAC.01021-12
   PubMed Web of Science ®Google Scholar
• Thorlacius-Ussing L, Sandholdt H, Nissen J, et al. Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: a pooled cohort study. Clin Infect Dis. 2021 Sep 7;73(5): 866–872. PMID: 33677515. 10.1093/cid/ciab201.
   PubMed Web of Science ®Google Scholar
• Abbas M, Rossel A, de Kraker MEA, et al. Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study. Clin Microbiol Infect. 2020;26(5):626–631. doi: 10.1016/j.cmi.2019.07.019
   PubMed Web of Science ®Google Scholar
• Jensen AG, Wachmann CH, Espersen F, et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002;162(1):25–3. doi: 10.1001/archinte.162.1.25
   PubMedGoogle Scholar
• Pandey N, Cascella M. Beta-lactam antibiotics. [updated 2022 sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545311/
   Google Scholar
• Fisher JF, Mobashery S. β-lactams against the fortress of the gram-positive Staphylococcus aureus bacterium. Chem Rev. 2021 Mar 24;121(6):3412–3463. Epub 2020 Dec 29. PMID: 33373523; PMCID: PMC8653850. doi: 10.1021/acs.chemrev.0c01010
   PubMed Web of Science ®Google Scholar
• La YJ, Kim HR, Oh DH, et al. Comparison of clinical outcomes for glycopeptides and beta-lactams in methicillin-susceptible Staphylococcus aureus bloodstream infections. Yonsei Med J. 2022 Jul;63(7):611–618. PMID: 35748072; PMCID: PMC9226830. doi: 10.3349/ymj.2022.63.7.611
   PubMed Web of Science ®Google Scholar
• Wong D, Wong T, Romney M, et al. Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016 Apr 26;15:27. PMID: 27112143; PMCID: PMC4845304. doi: 10.1186/s12941-016-0143-3
   PubMed Web of Science ®Google Scholar
• Brown NM, Goodman AL, Horner C, et al. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist. 2021 Feb 3;3(1):dlaa114. doi: 10.1093/jacamr/dlaa114
   PubMedGoogle Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 Jan 1;66(1):82–98. Erratum in: Am J Health Syst Pharm. 2009 May 15;66(10):887. PMID: 19106348. doi: 10.2146/ajhp080434
   PubMedGoogle Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48(12):4665–4672. doi: 10.1128/AAC.48.12.4665-4672.2004
   PubMed Web of Science ®Google Scholar
• Bellos I, Daskalakis G, Pergialiotis V. Relationship of vancomycin trough levels with acute kidney injury risk: an exposure-toxicity meta-analysis. J Antimicrob Chemother. 2020 Oct 1;75(10):2725–2734. PMID: 32417905. doi: 10.1093/jac/dkaa184
   PubMed Web of Science ®Google Scholar
• VG F Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665. doi: 10.1056/NEJMoa053783
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Giaccone A, Gentile I, et al. Daptomycin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis. Antibiotics. 2021 Aug 21;10(8):1014. PMID: 34439067; PMCID: PMC8389004. doi: 10.3390/antibiotics10081014
   Google Scholar
• Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841–5848. Published 2016 Sep 23. doi: 10.1128/AAC.00227-16
   PubMed Web of Science ®Google Scholar
• Moellering RC. Jr Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135–142. doi: 10.7326/0003-4819-138-2-200301210-00015
   PubMed Web of Science ®Google Scholar
• Hong XB, Yu ZL, Fu HB, et al. Daptomycin and linezolid for severe methicillin-resistant Staphylococcus aureus psoas abscess and bacteremia: a case report and review of the literature. World J Clin Cases. 2022 Mar 16;10(8):2550–2558. PMID: 35434080; PMCID: PMC8968589. doi:10.12998/wjcc.v10.i8.2550
   PubMed Web of Science ®Google Scholar
• Watkins RR, Lemonovich TL, TM F Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131–143. Epub 2012 Dec 11. PMID: 23271985; PMCID: PMC3526863. doi: 10.2147/CE.S33430
   PubMedGoogle Scholar
• Kawasuji H, Nagaoka K, Tsuji Y, et al. Effectiveness and safety of linezolid versus vancomycin, Teicoplanin, or Daptomycin against methicillin-resistant staphylococcus aureus bacteremia: a systematic review and meta-analysis. Antibiotics. 2023;12(4):697. doi: 10.3390/antibiotics12040697
   Google Scholar
• Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, et al. A review of population pharmacokinetic analyses of linezolid. Clin Pharmacokinet. 2022 Jun;61(6):789–817. Epub 2022 Jun 14. PMID: 35699914; PMCID: PMC9192929. doi: 10.1007/s40262-022-01125-2
   PubMed Web of Science ®Google Scholar
• Pea F, Cojutti PG, Baraldo M. A 10-year experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121(4):303–308. doi: 10.1111/bcpt.12797
   PubMed Web of Science ®Google Scholar
• Willekens R, Puig-Asensio M, Ruiz-Camps I, et al. Early oral switch to Linezolid for low-risk patients with staphylococcus aureus bloodstream infections: a propensity-matched cohort study. Clin Infect Dis. 2019;69(3):381–387. doi: 10.1093/cid/ciy916
   PubMed Web of Science ®Google Scholar
• Lv X, Alder J, Li L, et al. Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 63(7): e02252–18. doi:10.1128/AAC.02252-18
   PubMed Web of Science ®Google Scholar
• Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009 Oct;53(10):4069–79. Epub 2009 Jul 13. PMID: 19596875; PMCID: PMC2764163. doi: 10.1128/AAC.00341-09
   PubMed Web of Science ®Google Scholar
• Lee C-H, Tsai C-Y, Chia-Chin L, et al. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. J Antimicrob Chemother. 2015 Jan;70(1):257–263. doi: 10.1093/jac/dku335
   PubMed Web of Science ®Google Scholar
• Minter DJ, Appa A, Chambers HF, et al. Contemporary management of Staphylococcus aureus bacteremia-controversies in clinical practice. Clin Infect Dis. 2023 Nov 30;77(11):e57–e68. PMID: 37950887. doi: 10.1093/cid/ciad500
   PubMed Web of Science ®Google Scholar
• Ulloa ER, Singh KV, Geriak M, et al. Cefazolin and Ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2020 Sep 12;71(6):1413–1418. PMID: 31773134; PMCID: PMC7486850. doi:10.1093/cid/ciz995
   PubMed Web of Science ®Google Scholar
• Grillo S, Cuervo G, Carratalà J, et al. Impact of β-Lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: a propensity score-matched analysis. Clin Infect Dis. 2019 Oct 15;69(9):1480–1488. PMID: 30615122. doi: 10.1093/cid/ciz018
   PubMed Web of Science ®Google Scholar
• Cheng MP, Lawandi A, Butler-Laporte G, et al. Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus Bacteremia: a randomized, controlled trial. Clin Infect Dis. 2021 May 4;72(9):e196–e203. PMID: 32667982. doi:10.1093/cid/ciaa1000
   PubMed Web of Science ®Google Scholar
• Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”). Antimicrob Agents Chemother. 2010 Aug;54(8):3161–9. Epub 2010 Jun 14. PMID: 20547804; PMCID: PMC2916313. doi: 10.1128/AAC.00487-10
   PubMed Web of Science ®Google Scholar
• Mishra S, Lasek-Nesselquist E, Mathur A, et al. Phenotypic and genetic changes associated with the seesaw effect in MRSA strain N315 in a bioreactor model. J Glob Antimicrob Resist. 2022;28:249–253. doi: 10.1016/j.jgar.2022.01.013
   PubMed Web of Science ®Google Scholar
• Davis JS, Sud A, O’Sullivan MVN, et al. Combination of vancomycin and β-lactam therapy for methicillin-resistant staphylococcus aureus bacteremia: a Pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173–180. doi: 10.1093/cid/civ808
   PubMed Web of Science ®Google Scholar
• Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA Bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–537. doi: 10.1001/jama.2020.0103
   PubMed Web of Science ®Google Scholar
• Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019;63(5):e02483–18. doi: 10.1128/AAC.02483-18
   PubMed Web of Science ®Google Scholar
• Wang C, Ye C, Liao L, et al. Adjuvant β-lactam therapy combined with vancomycin or daptomycin for methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2020 [Published 2020 Oct 20];64(11):e01377–20. doi: 10.1128/AAC.01377-20
   PubMed Web of Science ®Google Scholar
• Grillo S, Puig-Asensio M, Schweizer ML, et al. The effectiveness of combination therapy for treating methicillin-susceptible Staphylococcus aureus bacteremia: a systematic literature review and a meta-analysis. Microorganisms. 2022 Apr 20;10(5):848. PMID: 35630294; PMCID: PMC9145429. doi: 10.3390/microorganisms10050848
   PubMed Web of Science ®Google Scholar
• Ye C, Wang C, Li Z, et al. The effect of combination therapy on mortality and adverse events in patients with Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Ther. 2021 Dec;10(4):2643–2660. Epub 2021 Oct 1. PMID: 34596881; PMCID: PMC8572899. doi: 10.1007/s40121-021-00539-y
   PubMed Web of Science ®Google Scholar
• Pujol M, Miró JM, Shaw E, et al. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus Bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis. 2021 May 4;72(9):1517–1525. PMID: 32725216; PMCID: PMC8096235. doi:10.1093/cid/ciaa1081
   PubMed Web of Science ®Google Scholar
• Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011 Jul 15;53(2):158–163. PMID: 21690622; PMCID: PMC3697476. doi: 10.1093/cid/cir340
   PubMed Web of Science ®Google Scholar
• Kiang TKL, Wilby KJ, Ensom MHH. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline. Clin Pharmacokinet. 2015;54(9):915–931. doi: 10.1007/s40262-015-0281-3
   PubMed Web of Science ®Google Scholar
• Azanza Perea JR, Sádaba Díaz de Rada B. Ceftobiprole: pharmacokinetics and PK/PD profile. Rev Esp Quimioter. 2019;32 Suppl 3:11–16.
   PubMed Web of Science ®Google Scholar
• Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of Ceftobiprole Medocaril for the treatment of Hospital- and community-acquired pneumonia in different patient populations. Clin Pharmacokinet. 2016;55(12):1507–1520. doi: 10.1007/s40262-016-0418-z
   PubMed Web of Science ®Google Scholar
• Gatti M, Pea F. Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections. Curr Opin Infect Dis. 2021;34(6):737–747. doi: 10.1097/QCO.0000000000000755
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Noel AR, Tomaselli S, et al. Pharmacodynamics of ceftaroline against staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2013;57(6):2451–2456. doi: 10.1128/AAC.01386-12
   PubMed Web of Science ®Google Scholar
• Sumi CD, Heffernan AJ, Lipman J, et al. What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review. Clin Pharmacokinet. 2019;58(11):1407–1443. doi: 10.1007/s40262-019-00791-z
   PubMed Web of Science ®Google Scholar
• Tam VH, Chang K-T, Zhou J, et al. Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017;72(5):1421–1428. doi: 10.1093/jac/dkx001
   PubMed Web of Science ®Google Scholar
• Gatti M, Cojutti PG, Pascale R, et al. Assessment of a PK/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections. Antibiotics. 2021;10(11):1311. doi: 10.3390/antibiotics10111311
   Google Scholar
• Singh R, Almutairi M, Alm RA, et al. Ceftaroline efficacy against high-MIC clinical staphylococcus aureus isolates in an in vitro hollow-fibre infection model. J Antimicrob Chemother. 2017;72(10):2796–2803. doi: 10.1093/jac/dkx214
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(1):372–380. doi: 10.1128/AAC.02531-14
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57(12):6348–6350. doi: 10.1128/AAC.01748-13
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008;52(10):3492–3496. doi: 10.1128/AAC.01273-07
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother. 2014;58(5):2512–2519. doi: 10.1128/AAC.02611-13
   PubMed Web of Science ®Google Scholar
• Gatti M, Pea F. Antimicrobial dose reduction in continuous renal replacement therapy: myth or real need? A practical approach for guiding dose optimization of novel Antibiotics. Clin Pharmacokinet. 2021;60(10):1271–1289. doi: 10.1007/s40262-021-01040-y
   PubMed Web of Science ®Google Scholar
• Kalaria S, Williford S, Guo D, et al. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy. 2021;41(2):205–211. doi: 10.1002/phar.2502
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Merelli M, De Stefanis P, et al. Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. Eur J Clin Pharmacol. 2018;74(12):1671–1672. doi: 10.1007/s00228-018-2535-0
   PubMed Web of Science ®Google Scholar
• Coppens A, Zahr N, Chommeloux J, et al. Pharmacokinetics/Pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2023;61(4):106765. doi: 10.1016/j.ijantimicag.2023.106765
   PubMed Web of Science ®Google Scholar
• Edlinger-Stanger M, Al Jalali V, Andreas M, et al. Plasma and lung tissue Pharmacokinetics of ceftaroline fosamil in patients undergoing cardiac surgery with cardiopulmonary bypass: an in vivo microdialysis study. Antimicrob Agents Chemother. 2021;65(10):e0067921. doi: 10.1128/AAC.00679-21
   PubMed Web of Science ®Google Scholar
• Chauzy A, Gregoire N, Ferrandière M, et al. Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance. J Antimicrob Chemother. 2022;77(11):3173–3179. doi: 10.1093/jac/dkac299
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Dominedò C, Garcia-Vidal C, et al. Ceftobiprole for the treatment of pneumonia. Rev Esp Quimioter. 2019;32 Suppl 3:17–23.
   PubMed Web of Science ®Google Scholar
• Riccobene TA, Pushkin R, Jandourek A, et al. Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects. Antimicrob Agents Chemother. 2016;60(10):5849–5857. doi: 10.1128/AAC.02755-15
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother. 2009;53(8):3294–3301. doi: 10.1128/AAC.00144-09
   PubMed Web of Science ®Google Scholar
• Helfer VE, Zavascki AP, Zeitlinger M, et al. Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues. Antimicrob Agents Chemother. 2022;66(9):e0074122. doi: 10.1128/aac.00741-22
   PubMed Web of Science ®Google Scholar
• Matzneller P, Lackner E, Lagler H, et al. Single- and repeated-dose Pharmacokinetics of ceftaroline in plasma and Soft Tissues of Healthy Volunteers for two different dosing regimens of ceftaroline Fosamil. Antimicrob Agents Chemother. 2016;60(6):3617–3625. doi: 10.1128/AAC.00097-16
   PubMed Web of Science ®Google Scholar
• Barbour A, Schmidt S, Sabarinath SN, et al. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother. 2009;53(7):2773–2776. doi: 10.1128/AAC.01409-08
   PubMed Web of Science ®Google Scholar
• Roujansky A, Martin M, Gomart C, et al. Multidrug-resistant Staphylococcus epidermidis ventriculostomy-related infection successfully treated by intravenous ceftaroline after failure of daptomycin treatment. World Neurosurg. 2020;136:221–225. doi: 10.1016/j.wneu.2020.01.013
   PubMed Web of Science ®Google Scholar
• Helfer VE, Dias BB, Lock GA, et al. Population pharmacokinetic modeling of free plasma and free brain concentrations of ceftaroline in healthy and methicillin-resistant Staphylococcus aureus-infected wistar rats. Antimicrob Agents Chemother. 2023;67(7):e0038223. doi: 10.1128/aac.00382-23
   PubMed Web of Science ®Google Scholar
• Cies JJ, Moore WS 2nd, Enache A, et al. Ceftaroline cerebrospinal fluid penetration in the treatment of a ventriculopleural shunt infection: a case report. J Pediatr Pharmacol Ther. 2020;25(4):336–339. doi: 10.5863/1551-6776-25.4.336
   PubMedGoogle Scholar
• Finazzi S, Luci G, Olivieri C, et al. Tissue penetration of antimicrobials in intensive care unit patients: a systematic review-part I. Antibiotics. 2022;11:1164. doi: 10.3390/antibiotics11091164
   Google Scholar
• Schmitt-Hoffman A, Engelhardt M, Spickermann J, et al. Bone penetration of the new-generation cephalosporin ceftobiprole in patients following hip replacement surgery [abstract]. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2016 - Amsterdam. 2016.
   Google Scholar
• Kuriakose SS, Rabbat M, Gallagher JC. Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother. 2015;70(3):953–954. doi: 10.1093/jac/dku464
   PubMed Web of Science ®Google Scholar
• Stucki A, Cottagnoud M, Acosta F, et al. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model. Antimicrob Agents Chemother. 2012;56(2):921–925. doi: 10.1128/AAC.01537-10
   PubMed Web of Science ®Google Scholar
• Stein GE, Yasin F, Smith C, et al. A pharmacokinetic/pharmacodynamic analysis of ceftaroline prophylaxis in patients with external ventricular drains. Surg Infect (Larchmt). 2015;16(2):169–173. doi: 10.1089/sur.2014.098
   PubMed Web of Science ®Google Scholar
• Roujansky A, Martin M, Gomart C, et al. Multidrug-Resistant Staphylococcus epidermidis Ventriculostomy-Related Infection Successfully Treated by Intravenous Ceftaroline after Failure of Daptomycin Treatment. World Neurosurg. 2020;136:221–225. doi: 10.1016/j.wneu.2020.01.013
   PubMed Web of Science ®Google Scholar
• File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66 Suppl 3:iii19–32.
   PubMedGoogle Scholar
• Low DE, File TM, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66 Suppl 3:iii33–44.
   PubMedGoogle Scholar
• Jandourek A, Smith A, Llorens L, et al. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia. Hosp Pract. 1995;42(1):75–78. 2014 Feb 2014 Feb. doi: 10.3810/hp.2014.02.1094
   Google Scholar
• Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161–171. doi: 10.1016/S1473-3099(14)71018-7
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 Suppl 4:p. iv41–51.
   Google Scholar
• Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Supplement 4):iv53–iv65. doi: 10.1093/jac/dkq255
   PubMedGoogle Scholar
• Nicholson SC, Welte T, File TM, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240–246. doi: 10.1016/j.ijantimicag.2011.11.005
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang Y-C, et al. A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia. Clinl Infect Dis. 2014;59(1):51–61. doi: 10.1093/cid/ciu219
   PubMed Web of Science ®Google Scholar
• Overcash JS, Kim C, Keech R, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET). Clinl Infect Dis. 2021;73(7):e1507–e1517. doi: 10.1093/cid/ciaa974
   PubMed Web of Science ®Google Scholar
• Holland TL, Cosgrove SE, Doernberg SB, et al. Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia. N Engl J Med. 2023;389(15):1390–1401. doi: 10.1056/NEJMoa2300220
   PubMed Web of Science ®Google Scholar
• Warren EF, Crocker RJ, Tabor B, et al. Successful use of nafcillin and ceftaroline combination therapy for persistent MSSA bacteraemia and endocarditis: a case series. JAC Antimicrob Resist. 2022 Dec 29;5(1):dlac129. PMID: 36601550; PMCID: PMC9798079. doi:10.1093/jacamr/dlac129
   PubMedGoogle Scholar
• Ahmad O, Crawford TN, Myint T. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline. Infect Dis Ther. 2020 Mar;9(1):77–87. Epub 2019 Nov 28. PMID: 31776844; PMCID: PMC7054513. doi: 10.1007/s40121-019-00277-2
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014 Oct 1;36(10):1317–33. Epub 2014 Jul 10. PMID: 25017183. doi:10.1016/j.clinthera.2014.05.061
   PubMed Web of Science ®Google Scholar
• Gritsenko D, Fedorenko M, Ruhe JJ, et al. Combination therapy with vancomycin and ceftaroline for refractory methicillin-resistant Staphylococcus aureus bacteremia: a case series. Clin Ther. 2017 Jan;39(1):212–218. Epub 2016 Dec 27. PMID: 28038791. doi: 10.1016/j.clinthera.2016.12.005
   PubMed Web of Science ®Google Scholar
• Morrisette T, Lagnf AM, Alosaimy S, et al. A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. Eur J Clin Microbiol Infect Dis. 2020 Nov;39(11):2199–2203. Epub 2020 Jun 13. PMID: 32535805. doi: 10.1007/s10096-020-03941-5
   PubMed Web of Science ®Google Scholar
• Hornak JP, Anjum S, Reynoso D. Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure. Ther Adv Infect Dis. 2019 Nov 7;6:2049936119886504. PMID: 31857898; PMCID: PMC691583. DOI:10.1177/2049936119886504
   Web of Science ®Google Scholar
• Patel D, Brown ML, Edwards S, et al. Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Int J Antimicrob Agents. 2023 Mar;61(3):106735. Epub 2023 Jan 20. PMID: 36690124; PMCID: PMC10023467. doi: 10.1016/j.ijantimicag.2023.106735
   PubMed Web of Science ®Google Scholar
• Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014 Jul 8;1(2):ofu046. Erratum in: Open Forum Infect Dis. 2015 Apr;2(2):ofv058. PMID: 25734118; PMCID: PMC4281789. doi: 10.1093/ofid/ofu046
   PubMedGoogle Scholar
• Johnson TM, Molina KC, Miller MA, et al. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021 Apr;57(4):106310. Epub 2021 Feb 18. PMID: 33609718. doi: 10.1016/j.ijantimicag.2021.106310
   PubMed Web of Science ®Google Scholar
• McCreary EK, Kullar R, Geriak M, et al. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2019 Dec 31;7(1): ofz538. PMID: 31938716; PMCID: PMC6951465. 10.1093/ofid/ofz538.
   PubMed Web of Science ®Google Scholar
• Cortes-Penfield N, Oliver NT, Hunter A, et al. Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia. Infect Dis. 2018 Aug;50(8):643–647. Epub 2018 Mar 6. PMID: 29508663; PMCID: PMC6109258. doi: 10.1080/23744235.2018.1448110
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Kosar J, Baxter M, et al. Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLeadership onAntimicrobialreal-life usage) registry. J Glob Antimicrob Resist. 2021 Mar;24:335–339. Epub 2021 Feb 1. PMID: 33540083: doi: 10.1016/j.jgar.2021.01.014
   PubMed Web of Science ®Google Scholar
• Zampino R, Gallo R, Salemme A, et al. Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital. Int J Antimicrob Agents. 2023 Aug;62(2):106883. Epub 2023 Jun 10. PMID: 37302772. doi: 10.1016/j.ijantimicag.2023.106883
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Corcione S, et al. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy. Int J Antimicrob Agents. 2023 Jul;62(1):106817. Epub 2023 Apr 13. PMID: 37061102. doi: 10.1016/j.ijantimicag.2023.106817
   PubMed Web of Science ®Google Scholar
• Oltolini C, Castiglioni B, Tassan Din CC, et al. Meticillin-resistant Staphylococcus aureus endocarditis: first report of daptomycin plus ceftobiprole combination as salvage therapy. Int J Antimicrob Agents. 2016 Jun;47(6):502–504. Epub 2016 Apr 25. PMID: 27211210. doi: 10.1016/j.ijantimicag.2016.04.006
   PubMed Web of Science ®Google Scholar
• Mahmoud E, Al Mansour S, Bosaeed M, et al. Ceftobiprole for treatment of MRSA blood stream infection: a case series. Infect Drug Resist 2020 Aug 3;13:2667–2672. PMID: 32821130; PMCID: PMC7422691. DOI:10.2147/IDR.S254395
   PubMed Web of Science ®Google Scholar
• Tascini C, Attanasio V, Ripa M, et al. Ceftobiprole for the treatment of infective endocarditis: a case series. J Glob Antimicrob Resist. 2020 Mar;20:56–59. Epub 2019 Jul 24. PMID: 31351247: doi: 10.1016/j.jgar.2019.07.020
   PubMed Web of Science ®Google Scholar
• Huang C, Chen I, Lin L. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus vancomycin or daptomycin monotherapy in adults with methicillin-resistant Staphylococcus aureus bacteremia-a meta-analysis. Antibiotics. 2022 Aug 15;11(8):1104. PMID: 36009973; PMCID: PMC9405305. doi: 10.3390/antibiotics11081104
   Google Scholar
• Destache CJ, Guervil DJ, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents. 2019 May;53(5):644–649. Epub 2019 Jan 31. PMID: 30711613. doi: 10.1016/j.ijantimicag.2019.01.014
   PubMed Web of Science ®Google Scholar
• Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012 May;67(5):1267–70. Epub 2012 Feb 6. PMID: 22311935. doi: 10.1093/jac/dks006
   PubMed Web of Science ®Google Scholar
• Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013 Nov;42(5):450–5. Epub 2013 Aug 11. PMID: 23993067. doi: 10.1016/j.ijantimicag.2013.07.005
   PubMed Web of Science ®Google Scholar
• Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014 May;58(5):2541–6. Epub 2014 Feb 18. PMID: 24550331; PMCID: PMC3993242. doi: 10.1128/AAC.02371-13
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02015–16. PMID: 27895012; PMCID: PMC5278749. doi: 10.1128/AAC.02015-16
   PubMed Web of Science ®Google Scholar
• Britt RS, Evoy KE, Lee GC, et al. Early use of ceftaroline fosamil in the United States Veterans Health Care System. Drugs. 2017 Aug;77(12):1345–1351. PMID: 28664412; PMCID: PMC5553123. doi: 10.1007/s40265-017-0785-2
   PubMed Web of Science ®Google Scholar
• Paladino JA, Jacobs DM, Shields RK, et al. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2014 Dec;44(6):557–63. Epub 2014 Sep 16. PMID: 25282169. doi: 10.1016/j.ijantimicag.2014.07.024
   PubMed Web of Science ®Google Scholar
• Mootz ML, Britt RS, Mootz AA, et al. Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hosp Pract. 2019 Oct;47(4):186–191. Epub 2019 Oct 14. PMID: 31578888; PMCID: PMC6883169. doi: 10.1080/21548331.2019.1676540
   PubMedGoogle Scholar
• Arshad S, Huang V, Hartman P, et al. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017 Apr;57:27–31. Epub 2017 Jan 25. PMID: 28131729: doi: 10.1016/j.ijid.2017.01.019
   PubMed Web of Science ®Google Scholar
• Werth BJ, Sakoulas G, Rose WE, et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013 Jan;57(1):66–73. Epub 2012 Oct 15. Erratum in: Antimicrob Agents Chemother. 2013 Mar;57(3):1565. PMID: 23070161; PMCID: PMC3535972. doi: 10.1128/AAC.01586-12
   PubMed Web of Science ®Google Scholar
• Sullivan EL, Turner RB, HR O Jr, et al. Ceftaroline-associated neutropenia: case series and literature review of incidence, risk factors, and outcomes. Open Forum Infect Dis. 2019 Mar 28;6(5):ofz168. PMID: 31123688; PMCID: PMC6524829. doi: 10.1093/ofid/ofz168
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008 Mar 1;46(5):647–55. PMID: 18225981. 10.1086/526527
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008 Jan;52(1):37–44. Epub 2007 Oct 22. PMID: 17954698; PMCID: PMC2223887. DOI:10.1128/AAC.00551-07
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, TM F Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012 Mar;39(3):240–246. Epub 2012 Jan 9. PMID: 22230331. DOI:10.1016/j.ijantimicag.2011.11.005
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51–61. Epub 2014 Apr 9. PMID: 24723282; PMCID: PMC4305133. 10.1093/cid/ciu219
   PubMed Web of Science ®Google Scholar
• Soriano A, Morata L. Ceftobripole: Experience in staphylococcal bacteremia. Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):24–28. PMID: 31364338; PMCID: PMC6755346. 10.1111/1469-0691.12144
   PubMedGoogle Scholar
• Moise PA, Amodio-Groton M, Rashid M, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother. 2013 Mar;57(3):1192–200. Epub 2012 Dec 17. PMID: 23254428; PMCID: PMC3591880. doi: 10.1128/AAC.02192-12
   PubMed Web of Science ®Google Scholar
• Barber KE, Werth BJ, Ireland CE, et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother. 2014 Nov;69(11):3006–10. Epub 2014 Jul 1. PMID: 24990867. doi: 10.1093/jac/dku236
   PubMed Web of Science ®Google Scholar
• Giuliano S, Angelini J, D’Elia D, et al. Ampicillin and ceftobiprole combination for the treatment of Enterococcus faecalis invasive infections: “The Times They are A-Changin”. Antibiotics. 2023 May 9;12(5):879. PMID: 37237782; PMCID: PMC10215339. doi: 10.3390/antibiotics12050879
   Google Scholar
• Wendland T, Daubner B, Pichler WJ. Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin. Br J Clin Pharmacol. 2011 Feb;71(2):297–300. PMID: 21219413; PMCID: PMC3040553. doi: 10.1111/j.1365-2125.2010.03832.x
   PubMed Web of Science ®Google Scholar
• Welte T, Kantecki M, Stone GG, et al. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults. Int J Antimicrob Agents. 2019 Oct;54(4):410–422. doi: 10.1016/j.ijantimicag.2019.08.012
   PubMed Web of Science ®Google Scholar
• Baines SD, Chilton CH, Crowther GS, et al. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2013 Aug;68(8):1842–9.
   PubMed Web of Science ®Google Scholar
• Girish C, Balakrishnan S. Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin. J Pharmacol Pharmacother. 2011;2(3):209–211. doi: 10.4103/0976-500X.83298
   PubMedGoogle Scholar
• Volk CF, Burgdorf S, Edwardson G, et al. Interleukin (IL)-1β and IL-10 host responses in patients with Staphylococcus aureus bacteremia determined by antimicrobial therapy. Clin Infect Dis. 2020 Jun 10;70(12): 2634–2640. PMID: 31365924; PMCID: PMC7286365. 10.1093/cid/ciz686.
   PubMed Web of Science ®Google Scholar
• Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2871–2875. doi: 10.1128/AAC.48.8.2871-2875.2004
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Zasowski EJ, Trinh TD, et al. Daptomycin plus β-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clin Infect Dis. 2020 Jun 24;71(1):1–10. PMID: 31404468. doi:10.1093/cid/ciz746
   PubMed Web of Science ®Google Scholar
• Cunha BA, Gran A. Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy. Int J Antimicrob Agents. 2015 Aug;46(2):225–6. Epub 2015 May 27. PMID: 26058777. doi: 10.1016/j.ijantimicag.2015.04.006
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J. In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2022 Dec 23;78(1):238–241. PMID: 36374572. doi: 10.1093/jac/dkac380
   PubMed Web of Science ®Google Scholar
• Gatti M, Viaggi B, Rossolini GM, et al. Targeted therapy of severe infections caused by Staphylococcus aureus in critically Ill adult patients: a multidisciplinary proposal of therapeutic algorithms based on real-world evidence. Microorganisms. 2023 Feb 3;11(2):394. doi: 10.3390/microorganisms11020394
   PubMed Web of Science ®Google Scholar
• Minejima E, Mai N, Bui N, et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020 Feb 3;70(4):566–573. PMID: 30949675; PMCID: PMC7768749. doi:10.1093/cid/ciz257
   PubMed Web of Science ®Google Scholar
• Greenberg JA, Hrusch CL, Jaffery MR, et al. Distinct T-helper cell responses to Staphylococcus aureus bacteremia reflect immunologic comorbidities and correlate with mortality. Crit Care. 2018 Apr 25;22(1):107. PMID: 29695270; PMCID: PMC5916828. doi: 10.1186/s13054-018-2025-x
   PubMedGoogle Scholar
• Kouijzer IJE, VG F Jr, Ten Oever J. Redefining Staphylococcus aureus bacteremia: A structured approach guiding diagnostic and therapeutic management. J Infect. 2023 Jan;86(1):9–13. Epub 2022 Nov 9. PMID: 36370898. doi: 10.1016/j.jinf.2022.10.042
   PubMed Web of Science ®Google Scholar